Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1303 • ACR Convergence 2020
Performance of Three Referral Algorithms for Diagnosing Axial Spondyloarthritis: Results from the Screening in Axial Spondyloarthritis for Psoriasis, Iritis, and Colitis Cohort
Ulrich Weber¹, Raj Carmona², James Yeung³, Jon Chan⁴, Liam Martin⁵, Ariel Masetto⁶, Stephanie Keeling⁷, Olga Ziouzina⁵, Sherry Rohekar⁸, Rana Dadashova⁹, Joel Paschke⁹, Amanda Carapellucci⁹, Robert G Lambert¹⁰, Walter Maksymowych⁷ and Sibel Aydin¹¹, ¹University of South Denmark, Odense, Denmark, ²St. Joseph's Healthcare, Hamilton, ON, Canada, ³James Yeung Rheumatology, Vancouver, BC, Canada, ⁴Artus Health Clinic, Vancouver, BC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸Lawson Health Research Institute, London, ON, Canada, ⁹CARE Arthritis, Edmonton, AB, Canada, ¹⁰University of Alberta and CARE Arthritis, Edmonton, AB, Canada, ¹¹University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada
Background/Purpose: Patients presenting with back pain and psoriasis, acute anterior uveitis (AAU), or inflammatory bowel disease (IBD), represent a high-risk population for the presence of…
Abstract Number: 1346 • ACR Convergence 2020
Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis
Runsheng Wang¹, Abhijit Dasgupta² and Michael Ward³, ¹Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ²NIAMS, Bethesda, ³National Institutes of Health, Bethesda, MD
Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous. In clinical practice, both patients and…
Abstract Number: 1858 • ACR Convergence 2020
Increased Proportion of TH17, TH22 and TC17 Cells and the Correlation to IL-22 and Clinical Parameters in Patients with Ankylosing Spondylitis from Northern Sweden
Kristina Lejon¹, Urban Hellman², Lan Do², Anjani Kumar² and Helena Forsblad-d'Elia³, ¹Department of Clinical microbiology, Infection and Immunology, Umeå University, Umeå, Sweden, ²Department of Public Health and Clinical Medicine, Rheumatology, Umeå, Sweden, ³Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Vasterbottens Lan, Sweden
Background/Purpose: Increased levels of TH17 and TH22 as well as TC17 and TC22 cells have previously been associated with ankylosing spondylitis (AS). The correlation between…
Abstract Number: 1885 • ACR Convergence 2020
Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial
Emilce Schneeberger¹, Gustavo Citera², Dario Ponce de Leon³, Annette Szumski⁴, Kenneth Kwok⁵, Mariel Cutri⁶ and Maxime Dougados⁷, ¹Department of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³PFIZER, LIMA, Peru, ⁴Syneos Health, Princeton, ⁵Pfizer, New York, NY, ⁶Pfizer, Buenos Aires, Argentina, ⁷Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) assesses axial spondyloarthritis (axSpA) with good internal consistency and discriminative capacity. However, a scientific calculator or electronic…
Abstract Number: 0371 • ACR Convergence 2020
Identifying Inadequate Response Among Ankylosing Spondylitis Patients Prescribed Biologics in a Real-world Commercially Insured Adult Population in the United States
Theresa Hunter¹, Michael Grabner², Keith Isenberg³, Mingyang Shan⁴, Chia-Chen Teng², Jeffrey Lisse⁴ and Jeffrey R Curtis⁵, ¹Eli Lilly and Company, Indianapolis, ²Healthcore, Inc, Wilmington, DE, ³Anthem, Inc, Indianapolis, IN, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The purpose of this analysis was to assess the frequency of inadequate response (IR) over 1 year from biologic initiation among ankylosing spondylitis (AS)…
Abstract Number: 1305 • ACR Convergence 2020
Is the Occurrence of Acute Anterior Uveitis Linked Primarily to Ankylosing Spondylitis (AS) or to HLA-B27? Results of a 35-Year Follow-Up Family Study of a Swiss Cohort of Patients with AS
Sjef van der Linden¹, Peter Villiger², Zhixiu Li³, Matthew Brown⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶ and Muhammad Khan⁷, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ²Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ³Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ⁴Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: Approximately 30% of HLA-B27(+) patients with ankylosing spondylitis (AS) have one or more episodes of acute anterior uveitis (AAU), a condition that is also…
Abstract Number: 1354 • ACR Convergence 2020
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis
Mark Siderius¹, Freke Wink¹, Anneke Spoorenberg¹ and Suzanne Arends¹, ¹University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…
Abstract Number: 1862 • ACR Convergence 2020
Genetic Influences on Occurrence of Axial Spondyloarthritis (axSpA) in First-degree Relatives During a Prospective Study Lasting 35 Years
Muhammad Khan¹, Sjef van der Linden², Peter Villiger³, Zhixiu Li⁴, Mohammad Khan⁵, Heinz Baumberger⁶, Hermine Zandwijk⁷ and Matthew Brown⁸, ¹Case Western Reserve University, Cleveland OH, Westlake, OH, ²Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ³Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁴Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ⁵Kent State University, Kent, OH, ⁶Retired, Flims, Tajikistan, ⁷Retired, Mortroux, Belgium, ⁸Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom
Background/Purpose: To investigate the recurrence rate (RR) of ankylosing spondylitis (AS) over a lifespan, probands with clinically diagnosed AS and their first-degree relatives (FDRs) were…
Abstract Number: 1889 • ACR Convergence 2020
Reliability and Validity of the PROMIS-29 Health Profile in Ankylosing Spondylitis Patients
Yvette Farran¹, Alexis Ogdie², John Reveille³ and Mark Hwang⁴, ¹McGovern Medical School at the University of Texas Health Sciences Center, Houston, TX, ²University of Pennsylvania, Philadelphia, PA, ³Department of Internal Medicine, University of Texas, Houston, TX, ⁴McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: The Patient Reported Outcomes Measurement Information System 29-Item Profile Measure (PROMIS-29) is a generic measure of health-related quality of life (HRQOL) that has seven…
Abstract Number: 0373 • ACR Convergence 2020
Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study
Emmanouil Rampakakis¹, Yoram Shir², John Sampalis¹, Martin Cohen², Michael Starr², Winfried Häuser³ and Mary-Ann Fitzcharles², ¹JSS Medical Research, St-Laurent, QC, Canada, ²McGill university, montreal, Canada, ³Technische Universität München, Munich, Germany
Background/Purpose: Recreational legalization of cannabis has influenced the medical use by patients. When only legal medical access was available in Canada, 4.3% of all rheumatology…
Abstract Number: 1306 • ACR Convergence 2020
High Prevalence of Previously Undiagnosed Axial Spondyloarthritis in Patients Referred with Anterior Uveitis and Chronic Back Pain
Rianne van Bentum¹, Frank Verbraak², Sanne Wolf³, Maarten Boers⁴, Stevie Tan⁵ and Irene van der Horst-Bruinsma¹, ¹Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ²Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ³Amsterdam University Medical Center location VUmc, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: To reduce the diagnostic delay in axial spondyloarthritis (axSpA), Rheumatology and Ophthalmology guidelines recommend to refer patients with acute anterior uveitis (AAU) and chronic…
Abstract Number: 1357 • ACR Convergence 2020
Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis
Adela Castro¹, Jesus Diaz², Guillermo Quiceno³ and John Cush⁴, ¹UT Southwestern, Dallas, TX, ²Universidad de los Andes, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX, ⁴University of Texas Southwestern Medical School, Dallas, TX
Background/Purpose: Active ankylosing spondylitis (AS) has been associated with poor quality of life and work disability in up to 50% of patients (1). There is…
Abstract Number: 1863 • ACR Convergence 2020
Clinical History as Tool for Diagnosis and Classification of Patients with Ankylosing Spondylitis (Axial Spondyloarthritis): Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort
Sjef van der Linden¹, Zhixiu Li², Matthew Brown³, Peter Villiger⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶ and Muhammad Khan⁷, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ²Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ³Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁴Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: Lack of sensitivity or specificity of symptoms may induce uncertainty in diagnosis and classification of AS/axSpA. We investigated if balanced sensitivity and specificity of…
Abstract Number: 1891 • ACR Convergence 2020
Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study
Ashit Syngle¹, Nidhi Garg² and Kanchan Chauhan¹, ¹Healing Touch City Clinic, Chandigarh, Chandigarh, India, ²Chitkara University, Rajpura, Punjab, India
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton and characterized by inflammatory back pain, leading to decreased mobility,…
Abstract Number: 0038 • ACR Convergence 2020
Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients – The Bioefficacy SpA Study
Ana Fernandes¹, Atlas Mashayekhi Sardoo², Miguel Bernardes³, Patrícia Pinto⁴, Helena Santos⁵, João Lagoas Gomes⁶, José Tavares-Costa⁷, José A. P. da Silva⁸, João Madruga-Dias⁹, Alexandra Bernardo¹⁰, Jean-Charles Gaillard¹¹, Lúcia Domingues¹², Sara Maia¹², Jean Armengaud¹¹, Jaime C. Branco¹³, Ana Varela Coelho¹⁴ and Fernando Pimentel-Santos¹⁵, ¹1.Instituto de Tecnologia Química e Biológica, Universidade NOVA de Lisboa; 2.Universidade de Trás-os-Montes e Alto Douro, Vila Real, Portugal, Oeiras, Portugal, ²3. CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ³4.Centro Hospitalar de S. João (Rheumatology Department) , Porto, Portugal, Porto, Portugal, ⁴5. Centro Hospitalar de Vila Nova de Gaia/Espinho (Rheumatology Department), Vila Nova de Gaia, Portugal, Vila Nova de Gaia, Portugal, ⁵6.Instituto Português de Reumatologia (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, ⁶7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, ⁷8.Unidade Local de Saúde do Alto Minho (Rheumatology Department), Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁸9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ⁹10.Centro Hospital Médio Tejo (Rheumatology Department), Torres Novas, Portugal, Dublin, Ireland, ¹⁰5.Centro Hospitalar de Vila Nova de Gaia/Espinho (Rheumatology Department), Vila Nova de Gaia, Portugal, Vila Nova de Gaia, Portugal, ¹¹11.Centre d énergie atomique (Laboratoire Innovations technologiques pour la Détection et le Diagnostic (Li2D), Service de Pharmacologie et Immunoanalyse (SPI)), Avignon, France, Avignon, France, ¹²3.CEDOC, NOVA Medical School. Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisboa, Portugal, ¹³3.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisboa, Portugal, ¹⁴1.Instituto de Tecnologia Química e Biológica, Universidade NOVA de Lisboa, Oeiras, Portugal, Oeiras, Portugal, ¹⁵3.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisbon, Portugal
Background/Purpose: Axial Spondyloarthritis (AS) is amongst the most common forms of inflammatory arthritis. Widely used in the treatment of axSpA, adalimumab is an engineered antibody…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.